MAVENIR
14.12.2021 09:03:17 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that Vodafone and Mavenir have completed the first data and Voice over LTE (VoLTE) call across a containerised 4G small cell Open RAN solution in a lab environment. The completed tests are the latest steps forward to delivering an open and vendor-interoperable 4G connectivity solution for small to medium-sized office locations.
Having first started work on a containerised indoor enterprise connectivity solution in January 2021, Vodafone has completed tests for an important stage of the technology roadmap. The plug-and-play small cell equipment can ensure comprehensive mobile coverage in every corner of the office. The solution will provide 4G coverage initially, making use of radio hardware from Sercomm and software from Mavenir (Open RAN).
This demonstration of a containerised solution is a major milestone in the evolution of connectivity equipment away from physical infrastructure to a digital cloud-based environment. Containerisation provides greater flexibility for customers, but also significant benefits in terms of speed and cost of deployment.
Containerisation means that software can be seamlessly transferred between equipment, platforms, and applications. Wind River provided its Containers as a Service (CaaS) software, part of Wind River Studio.
Moving forward, Vodafone and Mavenir will focus on finalising the packaging and automation of the solution before beginning trials with selected customers.
Open RAN technology separates software from hardware, meaning more flexibility for mobile operators and customers. The approach will see many companies providing the components that make up a mobile network site, where previously one vendor would have delivered the whole solution. The technology is widely accepted as a disruptor for the telecommunications industry, and Vodafone is one of the industry leaders in supporting the development of this vendor ecosystem.
Whereas much of the focus for Open RAN has been directed towards network infrastructure deployment on mobile sites throughout the UK, the technology can be implemented in an enterprise environment to support local connectivity requirements. As an interoperable and standardised technology, Open RAN solutions can be integrated with little disruption in a “plug and play” manner, interoperable with other Open RAN compliant vendors.
Andrea Dona, Chief Network Officer, Vodafone UK, said ; “Open RAN is opening doors to simplified and intuitive connectivity solutions. For our wider network deployment strategy, Open RAN is enabling us to work with a wider pool of suppliers and to avoid vendor lock-in scenarios that might prevent us from taking advantage of the latest innovations. The same could be said for enterprise connectivity solutions.
“From the moment Open RAN is deployed in an office environment, customers are no-longer locked into a single upgrade path. Working alongside Vodafone, customers can be more flexible in how connectivity solutions are adapted and upgraded as demands evolve in the future.”
Stefano Cantarelli, Executive Vice President and Chief Marketing Officer, Mavenir, said ; “Cloud Native and Open Solutions are becoming the new reality of the mobile world, and these include Radio Access and its containerised implementation. Open vRAN is a very flexible architecture that can serve any type of segment and Mavenir is really pleased to work with Vodafone in the enterprise business and achieved another first together. It is an opportunity to show that automated and AI controlled systems will simplify life to business and industry.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vodafone UK
Vodafone UK is a technology communications company that connects people, businesses and devices to help our customers benefit from digital innovation. Our services span mobile, fixed-line connections, home and office broadband, and the Internet of Things (IoT). www.vodafone.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
